cbd oil for epilepsy data

Cbd oil for epilepsy data

Efficacy of cannabinoids in pharmacoresistant epilepsy: A narrative review of the literature**

Iatreia , vol. 33 , no. 2 , pp. 167-176 , 2020

Universidad de Antioquia

Received: 19 July 2019

Accepted: 12 November 2019

SUMMARY: Epilepsy is a common neurological disorder that affects approximately 1% of the world’s pop7u-lation. About one third of those patients suffer from treatment-resistant epilepsy (TRE8), defined as failure to stop seizures despite adequate trials of at least two medications at therapeutic dosa-ges. There has been a growing interest in the development of novel antiepileptic drugs with diffe-rent mechanisms of action. This narrative review, based on 42 references retrieved from Scopus and Medline, discusses the scientific data from human and animal studies regarding the efficacy of cannabis-based treatment for epilepsy. Benefits have been described in preclinical and cli-nical studies in children, but ongoing research will clarify the real role of cannabinoids in TRE.

KEY WORDS: Cannabis, Drug Resistant Epilepsy, Review.

RESUMEN: La epilepsia es un desorden neurológico común que afecta aproximadamente al 1% de la pobla-ción mundial. Alrededor de un tercio de los pacientes sufren de epilepsia resistente al tratamiento, que se define como la falla de parar las crisis epilépticas a pesar de haber recibido tratamiento con dos medicamentos a dosis terapéuticas. Se ha visto interés en el desarrollo de medicamentos antiepilépticos con dife-rentes mecanismos de acción. Esta revisión narrativa se basó en 42 referencias extraídas de Scopus y Medli-ne, que discuten hallazgos científicos sobre estudios en humanos y animales acerca de la eficacia del cannabis para el tratamiento de epilepsia. Los beneficios se des-cribieron en estudios preclínicos y clínicos en niños, sin embargo investigaciones en curso clarificarán el papel real de los cannabinoides para la epilepsia resistente al tratamiento.

PALABRAS CLAVE: Epilepsia Refractaria, Revisión.

Epilepsy affects around 1% of the world population and up to 30% of them suffer from treatment-resistant epilepsy (TRE) 1 . In these patients, at least two tolerated, appropriately chosen and used antiepileptic drug (AED) regimens at therapeutic dosages fail to achieve sustained seizure remission 1 – 3 . Despite the availability of more than 20 AED and the continued research, discovery and approval of many new treatments with different mechanisms of action for epilepsy, the proportion of patients with TRE remains high 1 . Furthermore, the safety and sideeffect profile of AEDs remains a concern. Although it has improved in the past decades, central nervous system (CNS) related side effects are common, affecting quality of life 4 . Therefore, patients and families often seek alternative medication, which explains the rising interest in cannabis-based treatment for epilepsy.

Cannabis has been used medicinally for thousands of years. It was known and used by the Sumerians, Assyrians, Chinese, and Indians in a number of diseases as far back as the second millennium BC 5 . In the mid-1800s, William O’Shaugnessy reported the use of cannabis for the treatment of epilepsy. In the middle-to the late 19th century, two prominent English neurologists, Reynolds and Gowers, also noted benefits of cannabis for the treatment of epilepsy. Over the last 50 years, the main constituents of cannabis have been isolated and synthesized: delta-9-tetrahydrocannabinol (THC) was isolated in 1964 and synthesized in 1971, cannabi-diol (CBD) was isolated in 1940 and synthesized in the 1990s, supporting an endogenous system implicated in the pharmacology activity of CBD 6 .

There have been numerous reports in social media, surveys, preclinical studies and clinical trials of the efficacy of cannabis in the control and reduction of seizure frequency in TRE, especially in childhood resistant epilepsy. This is of great clinical importance since the repercussions of TRE are significant, with high rates of cognitive, behavioural and motor delays. This narrative review aims to summarize the existing literature regarding the efficacy of cannabinoids in seizure control.

Cannabis is a plant from the Cannabaceae family, which includes 170 species grouped in about 11 genera, which has three main species, Cannabis sativa , C. indica , and C. ruderalis . These plants contain over a hundred biologically active chemicals, known as cannabinoids, with the most abundant and best characterized being THC and CBD 7 . THC is the major psychoactive cons-tituent of cannabis, whereas CBD lacks psychoactive properties and has a low tolerance development rate. This is why CBD is considered to have a much wider therapeutic potential for epilepsy than THC 8 , 9 .

The understanding of the pharmacological activity of cannabinoids has increased greatly since the discovery of the cannabinoid (CB) receptors and the endocan-nabinoid system. Cannabinoids exert their function through the interaction with CB receptors found in the CNS and in the periphery. Two main CB receptors have been identified, CB1 is primarily located in the brain, whereas CB2 is expressed in peripheral nervous tissues and its distribution is predominantly associated with the immune system, such as the spleen and skin 10 , 11 . Both receptors belong to the class of G-protein coupled receptors which act on the second messenger system leading to intracellular effects: inhibition of the aden-ylyl cyclase enzyme leading to decreased levels of cAMP, stimulation of potassium channels leading to an increa-sed efflux of potassium, and inhibition of voltage-gated calcium channels which decreases calcium influx 12 . Anandamide and 2-arachidonoyl glycerol (2-AG) are the main brain endocannabinoids. They are small fatty acid derivates of arachidonic acid. Unlike conventional neurotransmitters, they are not stored in vesicles but rather produced in the intracellular environment when neuronal activity triggers an enzyme 13 , 14 .

It has previously been established that endocanna-binoids are produced under conditions of increased neuronal excitability and specific intracellular signalling. Therefore, during an epileptic seizure where there are large changes in transmembrane voltage, intracellular calcium increases and neurotransmitters such as acetylcholine and glutamate are released, a release of endocannabinoids is triggered 10 . There is evidence in many studies that exogenous cannabinoids can be neuroprotective and that CB1 activation by the seizureinduced release of endocannabinoids is also neuroprotective 10 , 15 – 17 . The purpose of this stu-dy is to perform a narrative review of the literature to find out the current evidence about the usage of phytocannabinoids for TRE.

A search was performed in MEDLINE (through Pubmed) using MeSH terms and free texts to identify articles regarding the use of cannabis and its compounds in the treatment of epilepsy. The first search was conducted on November 13, 2018 and conducted again on March 29, 2019. There were no language or year of publication restrictions. The following search strategy was used:

“Marijuana”[Mesh] OR “Ganja”[All Fields] OR “Hashish”[All Fields] OR “Hemp”[All Fields] OR “Bhang”[All Fields] OR “Cannabis”[Mesh] OR “Cannabinoids”[Mesh] OR “Cannabinol”[Mesh] OR “Dronabinol”[Mesh] OR “Tetrahydrocannabinol”[Mesh] OR “Cannabis”[All Fields] OR “Marihuana”[All Fields] OR “Marijuana”[All Fields] OR “CBD”[All Fields] OR “THC”[All Fields] OR “Medical marijuana”[Mesh] OR “Marijuana use”[Mesh] OR “Cannabinol”[All Fields] OR “Cannabinoids”[All Fields] OR “Tetrahydrocannabinol”[All Fields] OR “Dronabinol”[All Fields] AND “Epilepsy”[Mesh] OR “Epilepsy”[All Fields] OR “Seizures”[Mesh] OR “Seizures”[All Fields] OR “Epilepsies”[All Fields].

The search retrieved 868 references, the titles, and abstracts of systematic reviews, meta-analysis, case reports, review articles, and clinical trials were screened and the 42 which were considered most relevant were used for data extraction.

Preclinical studies: CBD and THC were found to be ineffective for animalmodel absence seizures, but they were effective against cortical focal seizures, limbic seizures, and tonic-clonic seizures. In animals with pilocarpine-induced temporal lobe epilepsy, pretreatment CBD reduced tonic-clonic seizures, without influencing mortality. THC and CBD were effective against limbic seizures produced by repetitive electrical stimulation in animal models 18 .

Karler et al., in 1987, found that THC had an anticonvulsant effect in various tests, however, it was proconvulsant in 2 other tests. Therefore THC could exert not only a depressant but also an excitatory effect 19 .

A study was performed to determine whether endocannabinoid signalling is affected in the epileptic human hippocampus. To this end, hippocampal samples were obtained from patients with therapyresistant temporal lobe epilepsy (TLE), and an analysis of the molecular components of the endocannabinoid system was analysed; CB1 receptor expression and the fraction of glutamatergic axon terminals equipped with CB1 were down-regulated in the epileptic hippocampus 20 . In patients with refractory mesial TLE, it was also noted that the endocannabinoid system and CB1 receptor were altered, suggesting a role in the pathophysiology of epilepsy 21 .

Clinical studies: The characteristics and conclusions of the relevant secondary studies, which were identified, are included in Table 1. One systematic review and meta-analysis found that patients who suffered from Lennox Gastaut syndrome or Dravet syndrome had a reduction in seizure frequency as compared to placebo. However, these patients experienced more adverse events 22 . Another systematic review found seizure reduction in patients with Lennox Gastaut syndrome 23 . There is some evidence that cannabinoids may reduce seizure frequency among children with drug-resistant epilepsy, however, this has only been evidenced for CBD and is not clear for ot

Author / Year Type of review Population Included studies Design Intervention Main results
Lattanzi, et al. 2018 22 Systematic Review and meta-analysis Pediatric and/or adult age, diagnosis of epilepsy, and seizures uncontrolled by concomitant AEDs, with Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) Four trials Randomized, double- or single-blinded, placebo-controlled, parallel-group add-on studies with active and control arms Oral CBD Adjunctive CBD in patients with LGS or DS experiencing seizures uncontrolled by concomitant anti-epileptic treatment regimens is associated with a greater reduction in seizure frequency and a higher rate of AEs than placebo.
Lattanzi, et al. 2018 23 Systematic review and meta‑analysis Patients of any gender, any ethnicity, paediatric and/or adult age, and diagnosis of LGS Two trials Randomized, placebo-controlled, single- or double-blinded trials Cannabidiol Adjunctive CBD resulted in a greater reduction in seizure frequency and a higher rate of AEs than placebo in patients with LGS presenting seizures uncontrolled by concomitant AEDs
Elliot, et al. 2018 24 Systematic review Children with epilepsy treated with cannabis‐based products Four RCTs and 19 NRSs were included Randomized controlled trials and non-randomized studies Cannabis‐based products Cannabidiol probably reduces seizures among children with drug‐resistant epilepsy (moderate certainty). At this time, the evidence base is primarily limited to cannabidiol, and these findings should not be extended to all cannabis‐based products
Stockings, et al. 2018 25 Systematic review Patients of any age, with any type of epilepsy or seizure 6 randomised controlled trials (RCTs), 30 observational studies RCTs, non-RCTs, quasi-experimental, before and after studies, prospective and retrospective cohort studies, case-control studies, analytical cross-sectional studies, self-report surveys, and case reports Plant-based and pharmaceutical cannabinoids Few high-quality RCTs have been conducted to date, and those that currently exist have tested CBD in paediatric samples with rare and serious forms of drug-resistant epilepsy. Of these existing studies, a reasonable proportion of patients experienced a decrease in seizure frequency when using pharmaceutical grade CBD products in addition to AEDs; however, minor AEs were likely and complete seizure freedom was unlikely.
Gloss & Vickrey 2014 26 Systematic review People of any age or sex, with epilepsy of any type four randomized trials Randomized controlled trials (RCTs) whether blinded or not Any type of marijuana, synthetic or natural THC, cannabinol, cannabidiol, or combinations that include these agents, for ingestion or inhalation for the control of seizures No reliable conclusions can be drawn at present regarding the efficacy of cannabinoids as a treatment for epilepsy. The dose of 200 to 300 mg daily of cannabidiol was safely administered to small numbers of patients generally for short periods of time, and so the safety of long term, cannabidiol treatment cannot be reliably assessed

Some of the studies identified a lack of adequately conducted trials regarding the efficacy of cannabinoids as a treatment for epilepsy 25 , 26 . One of the included systematic reviews concluded that “no reliable conclusions can be drawn at present regarding the efficacy of cannabinoids as a treatment for epilepsy”, owing to the lack of data from randomized, controlled trials of CBD, THC or other cannabinoids 26 .

Primary studies of multiple types were included. Their characteristics and main results are shown in Table 2. Three primary studies that were not included in the systematic reviews were retrieved. The three of them were prospective open-label trials and in all of them, there was a decrease in seizure frequency 27 – 29 . In one of these studies, an increase in seizure frequency was identified in a small number of patients. In this trial, both CBD and THC preparations were given 29 .

Author / Year Study Type Number of participants/ Doses Results
Cunha et al 9 ) 1980 Prospective, placebo-controlled trial of treatment-resistant epilepsy participants, followed for up to 4.5 months 15 participants; treatment: 8, placebo: 7. CBD doses 200-300 mg/daily Of the CBD group, 4 showed clinical improvement, of the placebo group none showed improvement.
Hess et al 30 2016 Case series of patients with TRE and a diagnosis of TSC received CBD for at least 6 months 18 participants. 5 mg/kg/daily increased up to maximum dose of 50 mg/kg/day There was a median percent change in weekly seizures of 48.8%. 4 patients had a percent decrease in seizures of >80%. 2 had a decrease of >90%
Maa and Figi ( 31 2014 Case report of 5-year-old girl with Dravet syndrome 1 participant treated with cannabis extract >90% of reduction in the frequency of generalized tonic-clonic seizures
Tzadok et al 32 2016 Retrospective case series of children and adolescents with refractory epilepsy in 4 centres in Israel. Followed for 3-12 months 74 patients treated with CBD-enriched oil at a dose of 1-20 mg/kg/day Most of the patients reported a reduction in seizure frequency (74.9%). 13 had a 75-100% reduction, 25 a 50-75% reduction, 9 had a 25-50% reduction and 19 had a <25% reduction
Devinsky et al 33 2017 Multicentric, double-blinded randomized placebo-controlled trial of children and young adults with Dravet syndrome and TRE 108 participants. 52 in the cannabidiol group and 56 in the placebo group In the cannabidiol group, the median change of convulsive seizure frequency reduction was of 38.9%, in the placebo group the median change was of 13.3%
Kaplan et al 34 2017 Prospective case series of patients with TRE and Sturge Weber syndrome 3 participants were given Epidiolex at a dose of 5-25 mg/kg/day Seizure frequency was significantly decreased. All subjects reported improvement in quality of life
Vezyroglou et al 27 2017 Prospective, open-label trial of children with TRE. Followed for 8 weeks 23 participants were given CBD at a dose of up to 16 mg&kg/day 47.8% of participants reported a >50% seizure reduction
Neubauer et al 35 2018 Retrospective case series of children and young adults with TRE, followed for 6 months 66 participants were given CBD to a maximum dose of 16 mg/kg/day 48.5% of patients had a 50% improvement or higher, 21.2% became seizure free
McCoy et al 28 2018 Prospective open-label trial of children with Dravet syndrome, followed for 20 weeks 14 participants were given CBD and THC preparations at 50:1 ratio, to a max dose of 16 mg/kg/day CBD 50% responder rate was 63% overall, 47% of participants had a reduction rate of 50-90%, 16% of >90%. 4 patients reported an increase in seizure frequency
Szaflarski et al 29 2018 Prospective open-label expanded access program of children and adults with TRE. Followed for 12 weeks 607 patients were given Epidiolex with a maximum dose of 25-50 mg/kg/day Median monthly seizure frequency of convulsive seizures was reduced by 51% and the frequency of total seizures was reduced by 48%
Thiele et al. 36 2018 Multicentric, randomised, double-blind, placebo-controlled trial of Cannabidiol in patients with seizures associated withLennox-Gastaut syndrome. 171 patients. 86 received cannabidiol and 85 received Placebo. The median percentage reduction in monthly drop seizure frequency from baseline was 43.9% (IQR −69.6 to −1.9) in the cannibidiol group and 21.8% (IQR −45·7 to 1·7) in the placebo group. Adverse events occurred in 74 (86%) of 86 patients in the cannabidiol group and 59 (69%) of 85 patients in the placebo group; most were mild or moderate.
Devinsky et al. 37 2018 Multicentric double-blind, placebo-controlled trial of patients with the Lennox-Gastaut syndrome (age range, 2 to 55 years) who had had two or more drop seizures per week during a 28-day baseline period. 225 patients. 76 received 20-mg cannabidiol, 73 received 10-mg cannabidiol, and 76 received placebo. The median percent reduction from baseline in drop-seizure frequency during the treatment period was 41.9% in the 20-mg cannabidiol group, 37.2% in the 10-mg cannabidiol group, and 17.2% in the placebo group (P=0.005 for the 20-mg cannabidiol group vs. placebo group, and P=0.002 for the 10-mg cannabidiol group vs. placebo group). The most common adverse events among the patients in the cannabidiol groups were somnolence, decreased appetite, and diarrhoea; these events occurred more frequently in the higher-dose group.
Devinsky et al. 38 2018 Multicentric prospective, open-label trial (not controlled) of patients aged 1-30 years, with intractable childhood-onset epilepsy. 162 patients in the safety and tolerability analysis, 137 patients in the in the efficacy analysis. Patients were given oral cannabidiol at 2-5 mg/kg per day, up-titrated until intolerance or to a maximum dose of 25 mg/kg or 50 mg/kg per day (dependent on study site). Adverse events were reported 79% of the patients within the safety group. Adverse events reported in more than 10% of patients were somnolence (n=41 [25%]), decreased appetite (n=31 [19%]), diarrhoea (n=31 [19%]), fatigue (n=21 [13%]), and convulsion (n=18 [11%]). The median reduction in monthly motor seizures was 36.5% (IQR 0-64.7)

A multicentric open-label interventional study was performed which included 137 patients with TRE -including patients with a diagnosis of Dravet syndrome and Lennox Gastaut síndrome who received CBD at a maximum dose of 25-50 mg/kg/day. There was a motor seizure reduction of 36.5% and 4% of patients were free of motor seizures during the 12 week treatment period 38 .

The lack of a placebo control group and risk of bias reduce the strength of conclusions that can be drawn from this study 39 .

Rosenberg et al reported the results of 137 patients with intractable childhood-onset epilepsy who received oral cannabidiol. The median reduction in motor seizures while receiving CBD was 36.5% (interquartile range 0-64.7) 39 .

GW Pharmaceuticals along with other investigators are performing placebo-controlled randomized clinical trials, some evaluating the efficacy of Epidiolex (purified CBD) in forms of TRE. Recently the data re-garding the first adequately-controlled phase 3 clinical trial of Epidiolex in patients with Dravet syndrome was published. It included 120 patients who were randomly assigned to receive Epidiolex at a dose of 20 mg/kg/day or placebo. Of the patients in the treatment group, 43% experienced at least a 50% reduction in seizure frequency, whereas in the placebo group the reduction was 27% 40 . Several patient and caregiver surveys have evaluated the efficacy of cannabis in epilepsy. In one survey of 117 caregivers assessing the efficacy and side effects of CBD exposure in children with infantile spasms and Lennox Gastaut syndrome, 5 respondents reported an increase in seizure frequency, 11 reported no change, and 100 (85%) reported a reduction in seizure frequency, 16 of those reporting complete seizure freedom 41 . Another survey performed in 2015 to 75 parents whose children were treated with oral cannabis extract in Colorado, reported that 33% of the patients had a seizure reduction frequency of more than 50%, although these responses were not associated with improvements in interictal EEG (electroencephalogram) when available 42 .

The interest in the use of cannabis as a treatment for epilepsy has increased over the last decades. In the early 1970’s several researchers found that CBD could reduce or block seizures in animal models 43 . These models provide powerful assays to validate the efficacy of cannabinoids in preventing seizures and reducing mortality in epilepsy 39 . The preclinical studies included in this review provide an explanation for the preferential use of CBD over THC in clinical studies, as THC has excitatory effects 19 . This has also been evidenced in the increase in seizure frequency in patients of one observational study in which preparations containing THC were used 28 .

On the other hand, CBD has been observed to have antiepileptic activity in preclinical studies with animal models, as well as clinical studies, making it the cannabinoid with more available evidence for the treatment of epilepsy. However, the clinical evidence supporting the use of CBD in epilepsy is limited, as few adequately-designed trials exist, and most address only paediatric patients 24 – 26 , 39 .

There are ongoing placebo-controlled randomized clinical trials especially addressing childhood refractory epilepsy syndromes, which have suggested that cannabis-based treatments might be effective. This novel therapeutic agent is warranted to be studied further, as it may have fewer adverse effects than conventional AEDs and produce an improvement in the quality of life of the patients.

Although this review included a large number of studies, its findings may be somewhat limited by the non-systematic nature of the review. Furthermore, a high proportion of the included evidence comes from observational studies, which limits the certainty concerning the effectiveness of cannabinoids in epilepsy.

Cannabinoids as a treatment for seizures is a novel therapy and it offers hope for patients with refractory epilepsy. Nonetheless, it is important to highlight that this therapy has not proven to be effective in all kinds of patients and therefore, it should not be used without a clear medical indication. The evidence we have so far from clinical studies have demonstrated the efficacy of CBD in the decrease of seizures, predominantly in patients diagnosed with Lennox Gastaut and Dravet syndrome.

Although few studies are evaluating the efficacy of cannabinoids in epileptic encephalopathies described previously, there are many studies which evaluate the quality of life of the patients using CBD, this has shown significant improvement, reducing not only seizures but improving motor and behavioural symptoms as well.

Another point of debate is the use of CBD as a monotherapy or as an add-on therapy, the literature suggests that we should not stop the baseline treatment of the patient, but use CBD in combination with other anticonvulsants, especially clobazam since this has shown to be the most effective in reducing seizures.

Despite the evidence mentioned in this review supporting the efficacy of cannabidiol- based therapies in treatment resistant epilepsy in children, there is little evidence and a lack of high-quality studies supporting the efficacy in adult population.

Therefore, there is a need for adequately designed clinical trials, especially in this population. Further research is needed to adequately establish the safety and effectiveness of cannabinoids in the treatment of epilepsy.

1. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry. 2001 Feb;178:107-15. DOI 10.1192/bjp.178.2.107.

2. O’Connell BK, Gloss D, Devinsky O. Cannabinoids in treatment-resistant epilepsy: A review. Epilepsy Behav. 2017;70(Pt B):341-8. DOI 10.1016/j.ye-beh.2016.11.012.

3. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77. DOI 10.1111/j.1528-1167.2009.02397.x.

4. Friedman D, Devinsky O, Killestein J. Cannabinoids in the treatment of epilepsy. N Engl J Med. 2016;374(1):1048-58. DOI 10.1056/NEJMra1407304.

5. Ashton CH. Biomedical benefits of cannabinoids? Addict Biol. 1999;4(2):111-26. DOI 10.1080/13556219971623.

6. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and epilepsy. Neurotherapeutics. 2015;12(4):747-68. DOI 10.1007/s13311-015-0375-5.

7. Perucca E. Cannabinoids in the treatment of epilepsy: ¿Hard evidence at last? J Epilepsy Res. 2017;7(2):61-76. DOI 10.14581/jer.17012.

8. Reddy DS, Golub VM. The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther. 2016;357(1):45-55. DOI 10.1124/jpet.115.230151.

9. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21(3):175-85. DOI 10.1159/000137430.

10. Alger BE. Endocannabinoids and their implications for epilepsy. Epilepsy Curr. 2004;4(5):169-73. DOI 10.1111/j.1535-7597.2004.04501.x.

11. Abood ME, Martin BR. Molecular neurobiology of the cannabinoid receptor. Int Rev Neurobiol. 1996;39:197-221. DOI 10.1016/S0074-7742(08)60667-4.

12. Lutz B. On-demand activation of the endocanna-binoid system in the control of neuronal excitability and epileptiform seizures. Biochem Pharmacol. 2004;68(9):1691-8. DOI 10.1016/j.bcp.2004.07.007.

13. Cohen S. Marijuana: ¿Does it have a possible thera-peutic use? JAMA. 1978;240(16):1761-3. DOI 10.1001/jama.240.16.1761.

14. Hirst RA, Lambert DG, Nottcutt WG. Pharmacology and potential therapeutic uses of cannabis. Br J Anaesth. 1998;81(1):77-84. DOI 10.1093/bja/81.1.77.

15. Di Marzo V. Biosynthesis and inactivation of endo-cannabinoids: relevance to their proposed role as neuromodulators. Life Sci. 1999;65(6-7):645-55. DOI 10.1016/S0024-3205(99)00287-8.

16. Zogopoulos P, Vasileiou I, Patsouris E, Theocharis S. The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects. J Appl Toxicol. 2013;33(4):246-64. DOI 10.1002/jat.2828.

17. Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, et al. CB1 cannabinoid receptors and ondemand defense against excitotoxicity. Science. 2003;302(5642):84-8. DOI 10.1126/scien-ce.1088208.

18. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiol Dis. 1998;5(6):534-51. DOI 10.1006/nbdi.1998.0220.

19. Turkanis SA, Karler R. Different cannabinoids exhibit different electrophysiological properties. NIDA Res Monogr. 1987;79:67-81. DOI 10.1037/e496672006-007.

20. Ludányi A, Eross L, Czirják S, Vajda J, Halász P, Watanabe M, et al. Downregulation of the CB1 canna-binoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J Neurosci. 2008;28(12):2976-90. DOI 10.1523/JNEUROSCI.4465-07.2008.

21. Goffin K, Van Paesschen W, Van Laere K. In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain. 2011;134(4):1033-40. DOI 10.1093/brain/awq385.

22. Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, et al. Efficacy and safety of cannabi-diol in epilepsy: A systematic review and meta-analysis. Drugs. 2018;78(17):1791-804. DOI 10.1007/s40265-018-0992-5.

23. Lattanzi S, Brigo F, Cagnetti C, Trinka E, Silvestrini M. Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: A systematic review and metaanalysis. CNS Drugs. 2018;32(10):905-16. DOI 10.1007/s40263-018-0558-9.

24. Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, et al. Cannabis-based products for pediatric epilepsy: A systematic review. Epilepsia . 2019;60(1):6-19. DOI 10.1111/epi.14608.

25. Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, et al. Evidence for cannabis and canna-binoids for epilepsy: a systematic review of contro-lled and observational evidence. J Neurol Neurosurg Psychiatry. 2018;89(7):741-53. DOI 10.1136/jnnp-2017-317168.

26. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;5(3):CD009270. DOI 10.1002/14651858.CD009270.pub3.

27. Vezyroglou K, Eltze C, Varadkar S, Carr L, O’Sullivan C, Ninnis E, et al. Efficacy and safety of cannabidiol as add-on therapy in drugresistant epilepsy, a single center experience. Eur J Paediatr Neurol. 2017;21:e87-e87. DOI 10.1016/j.ejpn.2017.04.699.

28. McCoy B, Wang L, Zak M, Al-Mehmadi S, Kabir N, Al-hadid K, et al. A prospective open-label trial of a CBD/THC cannabis oil in dravet syndrome. Ann Clin Transl Neurol. 2018;5(9):1077-88. DOI 10.1002/acn3.621.

29. Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, et al. Longterm safety and treatment effects of cannabidiol in children and adults with treatmentresistant epilepsies: Expanded access program results. Epilepsia . 2018;59(8):1540-8. DOI 10.1111/epi.14477.

30. Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia . 2016;57(10):1617-24. DOI 10.1111/epi.13499.

31. Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia . 2014;55(6):783-6. DOI 10.1111/epi.12610.

32. Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure. 2016;35:41-4. DOI 10.1016/j.sei-zure.2016.01.004.

33. Devinsky O, Cross JH, Wright S, Tang R, Fang F. Trial of cannabidiol for drug-resistant seizures in the Dra-vet syndrome. N Engl J Med. 2017;377(7):699. DOI 10.1056/NEJMc1708349.

34. Kaplan EH, Offermann EA, Sievers JW, Comi AM. Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome. Pediatr Neurol. 2017;71:18-23. DOI 10.1016/j.pediatrneurol.2017.02.009.

35. Neubauer D, Perkovic Benedik M, Osredkar D. Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia. Epilepsy Behav. 2018;81:79-85. DOI 10.1016/j.yebeh.2018.02.009.

36. Thiele EA, Marsh ED, French JA, Mazurkiewicz-Bel-dzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-96. DOI 10.1016/S0140-6736(18)30136-3.

37. Devinsky O, Patel AD, Cross JH, Villanueva V, Wi-rrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888-97. DOI 10.1056/NE-JMoa1714631.

38. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270-8. DOI 10.1016/S1474-4422(15)00379-8.

39. National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and can-nabinoids: the current state of evidence and recommendations for research. Washington, DC: The Na-tional Academies; 2017.

40. De Caro C, Leo A, Citraro R, De Sarro C, Russo R, Calignano A, et al. The potential role of cannabinoids in epilepsy treatment. Expert Rev Neurother. 2017;17(11):1069-79. DOI 10.1080/14737175.2017.1373019.

41. Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pedia-tric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138-41. DOI 10.1016/j.yebeh.2015.04.009.

42. Press C, Knupp K, Chapman K. Parental reporting of response to oral cannabis extracts as adjunctive treatment for medically refractory epilepsy. Epilepsy Curr. 2015;15:153. DOI 10.1016/j.yebeh.2015.02.043.

43. Mechoulam R, Parker LA, Gallily R. Cannabidiol: An overview of some pharmacological aspects. J Clin Pharmacol. 2002;42(11 SUPPL.):11S-19S. DOI 10.1002/j.1552-4604.2002.tb05998.x.

Status of Georgia’s Cannabidiol trials for treatment resistant epilepsy in children

In 2015, Georgia legalized limited use of medical marijuana, and in May of 2017, the number of conditions for which it could be used expanded. The medical community has focused in on cannabidiol, a compound that is one of the main constituents of cannabis but without the psychoactive properties that THC in marijuana has.

Currently at Augusta University, cannabidiol treatment is being provided to children with intractable epilepsy syndromes through the State of Georgia Cannabidiol Trial. This trial consists of two studies: CBD-01, which is approved by the FDA for two patients and CBD-02, which is a multi-site research study that is approved by the FDA and DEA; CBD-02 has open study locations in Augusta, Savannah and Atlanta and is being led by Dr. Yong Park, a pediatric epileptologist at Children’s Hospital of Georgia at Augusta University.

The children receiving cannabidiol have largely exhausted nearly all viable FDA-approved treatment options. The investigational medical product, Cannabidiol (CBD), is in the form of Epidiolex© and is being examined as an alternative treatment. Epidiolex© is manufactured and supplied by Greenwich Biosciences, a UK-based pharmaceutical company that currently manufactures CBD.

The CBD-01 study began enrollment in December 2014 and the CBD-02 study, an open-label, multi-center research study, began enrollment in January 2015. The enrolled patients were between the ages of 1 and 18 and were only eligible for participation in the study if they had tried at least four antiepileptic drugs, a combination of two antiepileptic drugs, and continued to have at least four countable seizures in two consecutive months (each defined as 28 days). The State of Georgia Cannabidiol Studies, CBD-01 and CBD-02, cumulatively have enrolled 53 patients. As of May 2017, there were 48 children continuing to receive treatment who had all completed 12 months (1 year) of treatment, 23 of the 48 children had completed 24 months (2 years) of treatment, and only 4 children had completed 30 months (2.5 years) of treatment.

The study design for CBD-02 is displayed in Figure 1 and includes a baseline period, titration period, maintenance period, optional secondary titration period, and treatment extension period (TEP).

Titration commences with a dose of 5 mg/kg/day and is increased every seven days until a dose of 25 mg/kg/day is achieved. After 26 weeks of treatment at 25 mg/kg/day, patient visits occur quarterly, unless the patient enters an optional secondary titration period or there is a medical reason that requires more frequent visits.

The secondary titration period provides incremental increases in the CBD dose of 5 mg/kg/day no sooner than every week, until the optimal efficacy and tolerability is achieved or the patient reaches a maximal dose of 50 mg/ kg/day. After any change in dose (i.e. increase, decrease, and titration period), patient visits occur every 28 days for 3 months, with a weekly safety telephone call. After 52 weeks of treatment, patients enter into the TEP, where visits normally occur quarterly. Throughout the entire study, patients record seizure frequency, seizure freedom, and seizure rescue medication daily, via an electronic patient diary app.

Interim data from the State of Georgia Cannabidiol Study was presented in 2016 at the National Meeting of the American Academy of Neurology and at the American Epilepsy Society Annual Meeting. The interim analysis demonstrated that in this open-label, small sample size study, the use of CBD as a treatment for children with mixed indications of treatment-resistant epilepsy was well tolerated, with a positive response for many patients. Conclusions of interim data presented on December 5, 2016 showed the following specific improvements:

  1. There was a decrease in major seizure frequency, with major seizures for these patients defined as complex partial with motor involvement, tonic, atonic, and generalized (including secondarily) tonic clonic seizures, during the initial titration period (reduction of 32 percent compared to baseline) as well as during all treatment periods when compared to baseline period (63 percent to 69 percent).
  2. The frequency of seizure-free days increased during CBD treatment when compared with baseline periods. The percent of patients reporting total seizure-free days during treatment periods ranged from 3 percent through 20 percent.
  3. Treatment has been well tolerated in doses up to 25 mg/kg/day, with no CBD-related serious adverse events. Side effects were noted in 90% of patients, but these were relatively minor (such as upper respiratory illness, diarrhea, irritability and flu-like symptoms (Park, et al. 2016). No patient withdrew from the study due to side effects.

The study continues with the goal of providing ongoing treatment with the study drug until it is authorized by the FDA and DEA for market use (i.e. becomes an approved prescription drug). GW Pharmaceuticals’ production of Epidiolex has been granted orphan status and has been placed into Fast Track Approval by the FDA fo r the treatment of both Dravet and Lennox-Gastaut Syndrome. The New England Journal of Medicine recently presented data in the May 2017 issue on the treatment of patients with Dravet syndrome. The article concluded that “among patients with the Dravet syndrome, cannabidiol resulted in a greater reduction in convulsive-seizure frequency than placebo and was associated with higher rates of adverse events” (Devinsky, et al. 2017). Although the results to date for both the State of Georgia Cannabidiol study and those conducted independently by GW Pharmaceuticals have demonstrated a positive response for many patients, the drug is still considered an investigational drug.

The results thus far are very encouraging with improvements noted in many patients who did not respond to available treatment options. Dr. Yong Park, the Principal Investigator of the State of Georgia Cannabidiol Studies project, is very thankful for this opportunity and for the support of the State of Georgia and Greenwich Biosciences in providing this treatment option to the children of Georgia.